Vertex Pharmaceuticals Inc / Ma.
- VRTX ยท Nasdaq
- Pharmaceutical Preparations
- Boston, MA
- 6,400 employees
- CIK 0000875320
Updated from SEC filings through
Top things to know
Executives
-
Reshma Kewalramani CEO & President 4, 2026-03-03 - Kristen Ambrose SVP & Chief Accounting Officer 4, 2026-09-01
- Amit Sachdev EVP Chief Patient & Ext Af Off 4, 2026-07-23
- Ourania Tatsis EVP, Chief Reg. & Quality Off. 4, 2026-07-23
- Duncan McKechnie EVP, Chief Commercial Officer 4, 2026-07-07
- Joy Liu EVP and Chief Legal Officer 4, 2026-07-06
Vertex Pharmaceuticals Inc / Ma is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Boston, MA. It trades as VRTX on Nasdaq. Revenue was $12.0B in the fiscal year ending December 31, 2025, +8.9% from the year before. It reported about 6,400 employees. Reshma Kewalramani is CEO & President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.0B 10-K, 2026-02-13 | $11.0B 10-K, 2026-02-13 | $9.9B 10-K, 2026-02-13 | $8.9B 10-K, 2025-02-13 | $7.6B 10-K, 2024-02-15 |
| Operating income | $4.2B 10-K, 2026-02-13 | -$233M 10-K, 2026-02-13 | $3.8B 10-K, 2026-02-13 | $4.3B 10-K, 2025-02-13 | $2.8B 10-K, 2024-02-15 |
| SG&A | $1.8B 10-K, 2026-02-13 | $1.5B 10-K, 2026-02-13 | $1.1B 10-K, 2026-02-13 | $945M 10-K, 2025-02-13 | $840M 10-K, 2024-02-15 |
| Net income | $4.0B 10-K, 2026-02-13 | -$536M 10-K, 2026-02-13 | $3.6B 10-K, 2026-02-13 | $3.3B 10-K, 2025-02-13 | $2.3B 10-K, 2024-02-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Lloyd Carney | Board member (per proxy) bio: Chief Executive Officer, Carney Global Ventures, LLC | DEF 14A, 2026-04-02 |
| Reshma Kewalramani | CEO & President | 4, 2026-03-03 |
| Suketu Upadhyay | Board member (per proxy) bio: Chief Financial Officer and Executive Vice President, | DEF 14A, 2026-04-02 |
| Kristen Ambrose SVP, Chief Accounting Officer at Vertex Pharmaceuticals | SVP & Chief Accounting Officer | 4, 2026-09-01 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 4, 2026-07-23 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 4, 2026-07-23 |
| Duncan McKechnie EVP & Chief Commercial Officer, Vertex Pharmaceuticals | EVP, Chief Commercial Officer | 4, 2026-07-07 |
| Joy Liu Chief Legal Officer at Vertex Pharmaceuticals | EVP and Chief Legal Officer | 4, 2026-07-06 |
| Mark E. Bunnage Executive Vice President & Chief Scientific Officer at Vertex Pharmaceuticals | EVP, Chief Scientific Officer | 4, 2026-05-19 |
| Diana McKenzie | Board member (per proxy) bio: Former Chief Information Officer, Workday | DEF 14A, 2026-04-02 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | 4, 2026-02-26 |
| Jonathan Biller | EVP and Chief Legal Officer | 4, 2026-02-26 |
| Charles F. Wagner | Executive Vice President and Chief Operating & Financial Officer (Principal Financial Officer) | 10-K, 2026-02-13 |
| Kristen C. Ambrose | Senior Vice President and Chief Accounting Officer (Principal Accounting Officer) | 10-K, 2026-02-13 |
| David Altshuler | EVP, Chief Scientific Officer | 4, 2026-01-26 |
| Grunsven Jasper van | EVP, CP and NPPO | 4, 2026-09-10 |
Shares and governance
| Shares outstanding | 253.5 million (as of October 31, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Public float | $113B (as of June 30, 2025) | 10-K, February 13, 2026 |
| Latest proxy statement | Meeting May 13, 2026 (filed April 2, 2026) | DEF 14A, April 2, 2026 |
| Auditor | Ernst & Young LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| July 2, 2026 | Ourania Tatsis EVP, Chief Reg. & Quality Off. | Sale | 1,500 | $787K | Form 4, July 7, 2026 |
| July 2, 2026 | Duncan McKechnie EVP, Chief Commercial Officer | Sale | 1,541 | $800K | Form 4, July 7, 2026 |
| July 1, 2026 | Joy Liu EVP and Chief Legal Officer | Sale | 828 | $416K | Form 4, July 6, 2026 |
| June 26, 2026 | Carmen Bozic EVP and CMO | Sale | 596 | $288K | Form 4, June 30, 2026 |
| June 18, 2026 | Carmen Bozic EVP and CMO | Sale | 1,020 | $471K | Form 4, June 23, 2026 |
| June 15, 2026 | Carmen Bozic EVP and CMO | Sale | 4,062 | $1.8M | Form 4, June 17, 2026 |
| June 5, 2026 | Carmen Bozic EVP and CMO | Sale | 1,745 | $785K | Form 4, June 9, 2026 |
| June 1, 2026 | Joy Liu EVP and Chief Legal Officer | Sale | 828 | $364K | Form 4, June 3, 2026 |
Recent 8-K events
- 8-K filed 2026-11-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-20
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-09-01
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-07
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-05-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-29
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-31
- Item 8.01 Other events
- 8-K filed 2026-02-12
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Vertex Pharmaceuticals Inc / Ma
- What does Vertex Pharmaceuticals Inc / Ma do?
- Vertex Pharmaceuticals Inc / Ma is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in Boston, MA.
- What is Vertex Pharmaceuticals Inc / Ma's revenue?
- $12.0B for the fiscal year ending December 31, 2025, from its 10-K filed February 13, 2026.
- Is Vertex Pharmaceuticals Inc / Ma profitable?
- Vertex Pharmaceuticals Inc / Ma reported net income of $4.0B for the fiscal year ending December 31, 2025.
- How many employees does Vertex Pharmaceuticals Inc / Ma have?
- About 6,400 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Vertex Pharmaceuticals Inc / Ma?
- Reshma Kewalramani, CEO & President, as named in a 4 filed March 3, 2026.
- Where is Vertex Pharmaceuticals Inc / Ma headquartered?
- Boston, MA.
- What is Vertex Pharmaceuticals Inc / Ma's stock ticker?
- VRTX on Nasdaq.
- What industry is Vertex Pharmaceuticals Inc / Ma in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Vertex Pharmaceuticals Inc / Ma's website?
- vrtx.com. Investor relations: https://investors.vrtx.com/.
- When does Vertex Pharmaceuticals Inc / Ma report earnings next?
- February 1, 2027. Source: estimate_8k_pattern.
- Is Vertex Pharmaceuticals Inc / Ma a public company?
- Yes. Vertex Pharmaceuticals Inc / Ma files with the SEC under CIK 0000875320 and trades as VRTX.
- Who audits Vertex Pharmaceuticals Inc / Ma?
- Ernst & Young LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Vertex Pharmaceuticals Inc / Ma are outstanding?
- 253.5 million shares as of October 31, 2026, from its 10-Q filed November 3, 2026.
- What is Vertex Pharmaceuticals Inc / Ma's public float?
- $113B as of June 30, 2025, as reported on the cover of its 10-K filed February 13, 2026.
- When is Vertex Pharmaceuticals Inc / Ma's annual shareholder meeting?
- May 13, 2026, per its proxy statement (DEF 14A) filed April 2, 2026.
- Have Vertex Pharmaceuticals Inc / Ma insiders traded stock recently?
- Since August 6, 2025, officers and directors reported 54 open-market sales worth about $158M and 2 purchases worth about $5.8M on Forms 4 and 5. The most recent: Ourania Tatsis (EVP, Chief Reg. & Quality Off.) sold 1,500 shares on July 2, 2026.